Last reviewed · How we verify

NCT07425626

Brillouin Scanning in Cataractous Eyes

Active, enrolled Last updated 23 February 2026
What this trial tests

trial testing Brillouin-Microscopy in Cataract in 50 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
11 March 2025
Primary endpoint
1 February 2026
1 June 2026

Quick facts

Lead sponsorPrim. Prof. Dr. Oliver Findl, MBA
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment50
Start date11 March 2025
Primary completion1 February 2026
Estimated completion1 June 2026
Sites1 location across Austria

Drugs / interventions tested

Conditions studied

Sponsor

Prim. Prof. Dr. Oliver Findl, MBA

Who can join

Adults 21 to 105, any sex, with Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To provide first results for biomechanical properties of cataractous lenses via Brillouin microscopy and correlations between LOCS III grading, cataractous lens scans from optical coherence tomography (OCT), and intraoperative phacoemulsification energy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cataract

Currently open trials in the same condition.

Other Prim. Prof. Dr. Oliver Findl, MBA trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07425626.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing